Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock?  Yahoo Finance

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance

Click here to get full coverage on New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan

New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use  Stock Titan

New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan

Click here to get full coverage on NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR) - Seeking Alpha

NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR)  Seeking Alpha

NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR) - Seeking Alpha

Click here to get full coverage on Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News - GuruFocus

Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News  GuruFocus

Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News - GuruFocus

Click here to get full coverage on NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - Zacks Investment Research

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial  Zacks Investment Research

NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - Zacks Investment Research

Click here to get full coverage on Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st

Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly?  simplywall.st

Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly? - simplywall.st

Click here to get full coverage on Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - The Motley Fool

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why  The Motley Fool

Prediction: Novocure (NVCR) Will Beat the Market. Here's Why - The Motley Fool

Click here to get full coverage on Trend Tracker for (NVCR) - news.stocktradersdaily.com

Trend Tracker for (NVCR)  news.stocktradersdaily.com

Trend Tracker for (NVCR) - news.stocktradersdaily.com

Click here to get full coverage on Novocure to Report Second Quarter 2025 Financial Results - Business Wire

Novocure to Report Second Quarter 2025 Financial Results  Business Wire

Novocure to Report Second Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? - Yahoo Finance

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect?  Yahoo Finance

Does NovoCure (NVCR) Have the Potential to Rally 105.5% as Wall Street Analysts Expect? - Yahoo Finance

Click here to get full coverage on NovoCure: Loading Up On Growth Catalysts - Seeking Alpha

NovoCure: Loading Up On Growth Catalysts  Seeking Alpha

NovoCure: Loading Up On Growth Catalysts - Seeking Alpha

Click here to get full coverage on NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week - simplywall.st

NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week  simplywall.st

NovoCure (NASDAQ:NVCR investor three-year losses grow to 80% as the stock sheds US$133m this past week - simplywall.st

Click here to get full coverage on NovoCure (NVCR) Q4 2024 Earnings Call Transcript - The Motley Fool

NovoCure (NVCR) Q4 2024 Earnings Call Transcript  The Motley Fool

NovoCure (NVCR) Q4 2024 Earnings Call Transcript - The Motley Fool

Click here to get full coverage on Piper Sandler Reiterates Overweight Rating on NVCR with $34 Price Target | NVCR Stock News - GuruFocus

Piper Sandler Reiterates Overweight Rating on NVCR with $34 Price Target | NVCR Stock News  GuruFocus

Piper Sandler Reiterates Overweight Rating on NVCR with $34 Price Target | NVCR Stock News - GuruFocus

Click here to get full coverage on NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth (NASDAQ:NVCR) - Seeking Alpha

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth (NASDAQ:NVCR)  Seeking Alpha

NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth (NASDAQ:NVCR) - Seeking Alpha

Click here to get full coverage on NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates  Yahoo Finance

NovoCure (NVCR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance

Click here to get full coverage on Mobility Giant FREENOW Achieves 100% RCS Conversion with Vonage API Integration | NVCR Stock News - Stock Titan

Mobility Giant FREENOW Achieves 100% RCS Conversion with Vonage API Integration | NVCR Stock News  Stock Titan

Mobility Giant FREENOW Achieves 100% RCS Conversion with Vonage API Integration | NVCR Stock News - Stock Titan

Click here to get full coverage on Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’ - Yahoo Finance

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’  Yahoo Finance

Jim Cramer on NovoCure Limited (NVCR): ‘I Have Watched Them For Years And Years And They’re Not Making Money’ - Yahoo Finance

Click here to get full coverage on Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus

Novocure (NVCR) Gains Support for Future Launch from Promising T  GuruFocus

Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus

Click here to get full coverage on Trading (NVCR) With Integrated Risk Controls - news.stocktradersdaily.com

Trading (NVCR) With Integrated Risk Controls  news.stocktradersdaily.com

Trading (NVCR) With Integrated Risk Controls - news.stocktradersdaily.com

Click here to get full coverage on (NVCR) Investment Report - news.stocktradersdaily.com

(NVCR) Investment Report  news.stocktradersdaily.com

(NVCR) Investment Report - news.stocktradersdaily.com

Click here to get full coverage on Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial - Insider Monkey

Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial  Insider Monkey

Zai Lab Limited (ZLAB) & NovoCure Limited (NVCR)’s TTFields Therapy Succeeds in Phase 3 Trial - Insider Monkey

Click here to get full coverage on Upcoming Piper Sandler Meeting in New York Focuses on NVCR | NVC - GuruFocus

Upcoming Piper Sandler Meeting in New York Focuses on NVCR | NVC  GuruFocus

Upcoming Piper Sandler Meeting in New York Focuses on NVCR | NVC - GuruFocus

Click here to get full coverage on NovoCure Announces Positive Phase 3 Trial Results - TipRanks

NovoCure Announces Positive Phase 3 Trial Results  TipRanks

NovoCure Announces Positive Phase 3 Trial Results - TipRanks

Click here to get full coverage on Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus

Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR)  GuruFocus

Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus

Click here to get full coverage on Novocure Announces Upcoming Investor Events - Business Wire

Novocure Announces Upcoming Investor Events  Business Wire

Novocure Announces Upcoming Investor Events - Business Wire

Click here to get full coverage on Novocure to present final secondary endpoint results from PANOVA-3 trial - TipRanks

Novocure to present final secondary endpoint results from PANOVA-3 trial  TipRanks

Novocure to present final secondary endpoint results from PANOVA-3 trial - TipRanks

Click here to get full coverage on NovoCure Appoints New President at Annual Meeting - TipRanks

NovoCure Appoints New President at Annual Meeting  TipRanks

NovoCure Appoints New President at Annual Meeting - TipRanks

Click here to get full coverage on Why NovoCure Stock Was Withering on Wednesday - The Motley Fool

Why NovoCure Stock Was Withering on Wednesday  The Motley Fool

Why NovoCure Stock Was Withering on Wednesday - The Motley Fool

Click here to get full coverage on Novocure Rings the Opening Bell - Nasdaq

Novocure Rings the Opening Bell  Nasdaq

Novocure Rings the Opening Bell - Nasdaq

Click here to get full coverage on Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus

Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News  GuruFocus

Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus

Click here to get full coverage on 1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street - The Motley Fool

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street  The Motley Fool

1 Stock Down 35% This Year You'll Regret Not Buying on the Dip, According to Wall Street - The Motley Fool

Click here to get full coverage on Novocure (NVCR) Faces Revised Price Target Amid Investor Opportunities | NVCR Stock News - GuruFocus

Novocure (NVCR) Faces Revised Price Target Amid Investor Opportunities | NVCR Stock News  GuruFocus

Novocure (NVCR) Faces Revised Price Target Amid Investor Opportunities | NVCR Stock News - GuruFocus

Click here to get full coverage on NovoCure’s Optune Lua Gains CE Mark Approval - TipRanks

NovoCure’s Optune Lua Gains CE Mark Approval  TipRanks

NovoCure’s Optune Lua Gains CE Mark Approval - TipRanks

Click here to get full coverage on NovoCure: Q4 Earnings Snapshot - NewsTimes

NovoCure: Q4 Earnings Snapshot  NewsTimes

NovoCure: Q4 Earnings Snapshot - NewsTimes

Click here to get full coverage on NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer - Seeking Alpha

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer  Seeking Alpha

NovoCure: PANOVA-3 Data Suggests A Potential Game-Changer For Pancreatic Cancer - Seeking Alpha

Click here to get full coverage on Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - Business Wire

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update  Business Wire

Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update - Business Wire

Click here to get full coverage on NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript  Insider Monkey

NovoCure Limited (NASDAQ:NVCR) Q1 2025 Earnings Call Transcript - Insider Monkey

Click here to get full coverage on NovoCure's Earnings: A Preview - Nasdaq

NovoCure's Earnings: A Preview - Nasdaq

Click here to get full coverage on Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting  Business Wire

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Business Wire

Click here to get full coverage on Lobbying Update: $110,000 of NOVOCURE INC. lobbying was just disclosed - Quiver Quantitative

Lobbying Update: $110,000 of NOVOCURE INC. lobbying was just disclosed  Quiver Quantitative

Lobbying Update: $110,000 of NOVOCURE INC. lobbying was just disclosed - Quiver Quantitative

Click here to get full coverage on Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Business Wire

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland  Business Wire

Novocure Inaugurates New Global Headquarters in Canton of Zug, Switzerland - Business Wire

Click here to get full coverage on Why NovoCure Stock Skyrocketed This Week - Nasdaq

Why NovoCure Stock Skyrocketed This Week  Nasdaq

Why NovoCure Stock Skyrocketed This Week - Nasdaq

Click here to get full coverage on Why NovoCure Stock Leaped 4% Higher Today - The Motley Fool

Why NovoCure Stock Leaped 4% Higher Today  The Motley Fool

Why NovoCure Stock Leaped 4% Higher Today - The Motley Fool

Click here to get full coverage on Novocure Reports First Quarter 2025 Financial Results - Business Wire

Novocure Reports First Quarter 2025 Financial Results  Business Wire

Novocure Reports First Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus

Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR)  GuruFocus

Insider Sell Alert: Frank Leonard Sells 15,036 Shares of NovoCure Ltd (NVCR) - GuruFocus

Click here to get full coverage on Novocure executive sells shares for $296,256 - Investing.com

Novocure executive sells shares for $296,256  Investing.com

Novocure executive sells shares for $296,256 - Investing.com

Click here to get full coverage on Biotech Stock Launches 49% On Pancreatic Cancer Success - Investor's Business Daily

Biotech Stock Launches 49% On Pancreatic Cancer Success  Investor's Business Daily

Biotech Stock Launches 49% On Pancreatic Cancer Success - Investor's Business Daily

Click here to get full coverage on Novocure shares fall as Q4 earnings miss overshadows revenue beat - Investing.com

Novocure shares fall as Q4 earnings miss overshadows revenue beat  Investing.com

Novocure shares fall as Q4 earnings miss overshadows revenue beat - Investing.com

Click here to get full coverage on Analysts Are Updating Their NovoCure Limited (NASDAQ:NVCR) Estimates After Its First-Quarter Results - 富途牛牛

Analysts Are Updating Their NovoCure Limited (NASDAQ:NVCR) Estimates After Its First-Quarter Results  富途牛牛

Analysts Are Updating Their NovoCure Limited (NASDAQ:NVCR) Estimates After Its First-Quarter Results - 富途牛牛

Click here to get full coverage on NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com UK

NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data  Investing.com UK

NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com UK

Click here to get full coverage on Novocure Ltd earnings beat by $0.18, revenue topped estimates - Investing.com

Novocure Ltd earnings beat by $0.18, revenue topped estimates  Investing.com

Novocure Ltd earnings beat by $0.18, revenue topped estimates - Investing.com

Click here to get full coverage on NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial  Benzinga

NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Benzinga

Click here to get full coverage on NovoCure Q4 EPS Misses, Revenue Matches - Nasdaq

NovoCure Q4 EPS Misses, Revenue Matches  Nasdaq

NovoCure Q4 EPS Misses, Revenue Matches - Nasdaq

Click here to get full coverage on NovoCure Surpasses Q1 Expectations - Nasdaq

NovoCure Surpasses Q1 Expectations  Nasdaq

Novocure Ltd (NVCR)

Price Chart

Key Statistics

Technicals

About NVCR

Latest News

NovoCure (NVCR) Soars 5.3%: Is Further Upside Left in the Stock? - Yahoo Finance

New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan

NovoCure Limited: Profitability Remains Elusive (NASDAQ:NVCR) - Seeking Alpha

Advanced Charts

Top Gainers

Top Losers